XML 50 R34.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenues - Disaggregation of Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 5,143 | $ 5,685 | $ 10,691 | $ 10,966
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 3,784 | 4,073 | 7,790 | 7,891
Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 786 | 1,099 | 1,761 | 2,037
Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 573 | 513 | 1,140 | 1,038
Atripla |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 103 | 152 | 198 | 323
Atripla | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 95 | 122 | 176 | 255
Atripla | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 5 | 26 | 12 | 42
Atripla | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 3 | 4 | 10 | 26
Biktarvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 1,604 | 1,116 | 3,297 | 1,909
Biktarvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 1,350 | 1,023 | 2,762 | 1,762
Biktarvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 153 | 73 | 334 | 121
Biktarvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 101 | 20 | 201 | 26
Complera/Eviplera |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 72 | 123 | 148 | 238
Complera/Eviplera | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 27 | 42 | 51 | 86
Complera/Eviplera | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 42 | 72 | 89 | 134
Complera/Eviplera | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 3 | 9 | 8 | 18
Descovy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 417 | 358 | 875 | 700
Descovy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 337 | 246 | 700 | 479
Descovy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 46 | 69 | 107 | 137
Descovy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 34 | 43 | 68 | 84
Genvoya |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 816 | 980 | 1,640 | 1,995
Genvoya | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 646 | 733 | 1,258 | 1,461
Genvoya | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 109 | 177 | 260 | 370
Genvoya | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 61 | 70 | 122 | 164
Odefsey |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 382 | 387 | 791 | 784
Odefsey | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 273 | 266 | 542 | 548
Odefsey | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 98 | 111 | 225 | 217
Odefsey | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 11 | 10 | 24 | 19
Stribild |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 59 | 108 | 112 | 204
Stribild | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 39 | 78 | 73 | 145
Stribild | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 12 | 24 | 29 | 42
Stribild | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 8 | 6 | 10 | 17
Truvada |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 387 | 718 | 793 | 1,324
Truvada | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 370 | 657 | 753 | 1,208
Truvada | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 6 | 41 | 14 | 74
Truvada | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 11 | 20 | 26 | 42
Other HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 28 | 15 | 36 | 32
Other HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 11 | 9 | 14 | 20
Other HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 1 | 1 | 3 | 2
Other HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 16 | 5 | 19 | 10
Revenue share - Symtuza |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 132 | 84 | 244 | 150
Revenue share - Symtuza | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 90 | 55 | 162 | 97
Revenue share - Symtuza | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 40 | 29 | 78 | 53
Revenue share - Symtuza | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 2 | 0 | 4 | 0
AmBisome |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 95 | 105 | 214 | 198
AmBisome | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 10 | 10 | 28 | 18
AmBisome | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 49 | 60 | 108 | 117
AmBisome | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 36 | 35 | 78 | 63
Ledipasvir/Sofosbuvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 67 | 193 | 179 | 418
Ledipasvir/Sofosbuvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 24 | 86 | 77 | 203
Ledipasvir/Sofosbuvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 4 | 22 | 15 | 49
Ledipasvir/Sofosbuvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 39 | 85 | 87 | 166
Letairis |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 80 | 204 | 163 | 401
Letairis | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 80 | 204 | 163 | 401
Letairis | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 0 | 0 | 0 | 0
Letairis | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 0 | 0 | 0 | 0
Ranexa |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 1 | 19 | 9 | 174
Ranexa | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 1 | 19 | 9 | 174
Ranexa | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 0 | 0 | 0 | 0
Ranexa | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 0 | 0 | 0 | 0
Sofosbuvir/Velpatasvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 335 | 493 | 899 | 984
Sofosbuvir/Velpatasvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 165 | 219 | 476 | 449
Sofosbuvir/Velpatasvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 57 | 156 | 179 | 310
Sofosbuvir/Velpatasvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 113 | 118 | 244 | 225
Vemlidy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 151 | 116 | 287 | 217
Vemlidy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 76 | 71 | 149 | 136
Vemlidy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 7 | 5 | 14 | 9
Vemlidy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 68 | 40 | 124 | 72
Viread |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 65 | 75 | 105 | 147
Viread | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 3 | 9 | 7 | 21
Viread | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 8 | 28 | 19 | 42
Viread | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 54 | 38 | 79 | 84
Vosevi |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 39 | 75 | 87 | 138
Vosevi | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 27 | 53 | 60 | 98
Vosevi | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 6 | 15 | 17 | 31
Vosevi | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 6 | 7 | 10 | 9
Yescarta |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 156 | 120 | 296 | 216
Yescarta | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 95 | 99 | 198 | 189
Yescarta | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 56 | 21 | 93 | 27
Yescarta | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 5 | 0 | 5 | 0
Zydelig |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 18 | 26 | 38 | 53
Zydelig | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 8 | 12 | 16 | 23
Zydelig | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 9 | 14 | 21 | 29
Zydelig | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 1 | 0 | 1 | 1
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 60 | 140 | 123 | 202
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 43 | 41 | 85 | 77
Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 16 | 97 | 34 | 117
Other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 1 | 2 | 4 | 8
Total product sales |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 5,067 | 5,607 | 10,534 | 10,807
Revenues | 5,067 | 5,607 | 10,534 | 10,807
Total product sales | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 3,770 | 4,054 | 7,759 | 7,850
Total product sales | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 724 | 1,041 | 1,651 | 1,923
Total product sales | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenues | 573 | 512 | 1,124 | 1,034
Royalty, contract and other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 76 | 78 | 157 | 159
Royalty, contract and other revenues | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 14 | 19 | 31 | 41
Royalty, contract and other revenues | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 62 | 58 | 110 | 114
Royalty, contract and other revenues | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 0 | $ 1 | $ 16 | $ 4

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsVoseviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |